The VICC.ORG Investigator Directory

Ingrid A. Mayer, M.D., M.S.C.I.

Assistant Professor of Medicine (Hematology/Oncology)
Clinical Director, Breast Cancer Program
VICC Member
Medical Oncologist

Patient Contact Information:

615-322-2064

Vanderbilt Breast Center One Hundred Oaks
719 Thompson Lane, Suite 25000
Nashville, TN 37204
Phone: 615-322-2064; Referring Physicians: 615-343-9283
Fax: 615-343-7622

Healthcare Provider Contact Information:

Vanderbilt-Ingram Cancer Center
777 Preston Building
Nashville, TN 37232-6307
615-936-3831
Fax: 615-343-7602

Profile

Dr. Ingrid Mayer graduated medical school in 1993 at the Federal University of Sao Paulo, Brazil. She completed her Internal Medicine Residency and Chief Residency in 1998 at the University of Illinois at Chicago, where she also did her Hematology/ Oncology Fellowship training from 1998 through 2001. During this time, she worked in the laboratory setting with MAPK signaling pathway in Chronic Myelogenous Leukemia, for which she received an American Society of Clinical Oncology (ASCO) Young Investigator Award.

In 2003, Dr. Mayer became an Assistant Professor of Medicine in the Division of Hematology/ Oncology at the Vanderbilt University School of Medicine, where she completed a Master of Science in Clinical Investigation (MSCI) Program in May 2006. She has obtained intramural support through the Vanderbilt Physician Scientist Development (VPSD) Award Program and a Cancer Center Grant Support (CCSG) Award to identify relevant tumor antigens/targets in breast cancer tumor samples. She has intensively worked in translational projects related to targeted therapies in breast cancer, obtaining a Pilot Project from the Breast Cancer SPORE in 2005. She has also obtained a Breast Cancer Research Foundation – American Association for Cancer Research (BCRF-AACR) Grant for Translational Breast Cancer Research to explore combined endocrine and ErbB inhibition in ER+/HER2+ breast cancers in 2007, a K23 Career Development Award to explore targeted therapies in breast cancer, and is also!
  co-Leader in three of the four research projects of the NCI-funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, Director).

Dr. Mayer is a key component of the Vanderbilt-Ingram Cancer Center (VICC) Breast Cancer Program, where her role is to implement and conduct investigator-initiated, mechanism-based clinical and translational trials in breast cancer, focusing in novel diagnostic and therapeutic approaches. Administratively, she directs the Clinical Core of the VICC Breast Cancer SPORE. She is a member of the Eastern Cooperative Oncology Group (ECOG) Breast Committee, the National Comprehensive Cancer Network (NCCN) Breast Cancer Panel of Experts, and had served in the American Society of Clinical Oncology (ASCO) Scientific Review Committee for two years.

Research Specialty:

Breast Cancer - Targeted Therapies

Research Description:

My research focus is on new therapeutic strategies focusing on the phosphatidylinositol-3 kinase (PI3K)/Akt and correlated pathways in triple-negative, hormone-refractory and HER2-overexpressing refractory breast cancers, using biologically-based targeted agents. I plan to perform molecular analysis of individual breast cancers in an attempt to determine how the biology of the cancer affects the response to the therapeutic agent. It is also my goal to play a key role in elucidating mechanisms of therapy resistance for patients with triple-negative, resistant ER-positive and resistant HER2-positive breast cancers. Ultimately this will result in better and more rational patient/therapy selection.

My role as a clinical investigator are as follows:

1) Develop a Clinical Breast Cancer Research Program with strong links to laboratory efforts throughout the medical center and if necessary, external to the institution. This goal involves collaboration with prestigious investigators within and outside Vanderbilt, and consists of a bidirectional process: observations made in the clinic and correlative studies in tissue samples from clinical trial patients with breast cancer lead basic scientists to investigate new areas of research. Conversely, pre-clinical data focused on relevant signaling pathways in breast cancer are the basis for development and implementation of novel hypothesis-driven clinical trials.

2) Expand preclinical therapeutic testing with tumors freshly obtained from the breast cancer patients in clinical trials. Tissue collection (primary tumor paraffin blocks and/or fresh frozen tissue) in all investigator-initiated breast cancer clinical trials is required for patient enrollment. Thanks to our Multidisciplinary Breast Cancer Clinic, we have been extremely successful in enrolling patients to clinical trials requiring research biopsies.

3) Develop and perform hypothesis-driven, translational clinical trials with biologically-based targeted therapeutics that are based on preclinical findings obtained in vitro and/or in vivo in human and murine systems, to address the most important issues in breast cancer .

My research endeavors are focused on the role of the following correlated key cell signaling pathways in breast cancer: PI3K/Akt, erbB (EGFR, HER2/neu), and Insulin-like Growth Factor (IGF)-1 pathways. I have developed targeted-oriented clinical trials addressing the role of these pathways in the development of resistance to antiestrogens and trastuzumab, as well as their role in triple-negative, basal-like tumors. This strategy will provide better understanding of breast cancer biology and of the molecular determinants of clinical efficacy, by optimally characterizing the molecular features of the breast cancer to be treated. This will foster target-assay development in a more limited number of patients. In turn, these results will be instrumental in expediting subsequent development of molecularly targeted agents, providing a platform for prioritization of novel combinations and elucidation of preferential mechanisms of escape from these therapies.

Examples of some of my investigator-initiated clinical trials include:

VICCBRE0949: A phase I/II study of cisplatin, paclitaxel and RAD001 in patients with metastatic breast cancer

VICCBRE0904: A phase II neoadjuvant study of cisplatin, paclitaxel with or without RAD001 in patients with triple-negative locally advanced breast cancer

VICCBRE09112: A phase II trial of endocrine therapy in combination with OSI-906 (an IGF-1R inhibitor) and erlotinib (Tarcevaâ„¢, an EGFR inhibitor) in patients with hormone-sensitive metastatic breast cancer

VICCBRE0942: A pre-surgical trial of metformin in patients with operable early breast cancer

VICCBRE0983: A Prospective Clinical Trial evaluating Potential Biomarkers for Bevacizumab Induced Hypertension

Clinical Interest:

Dr. Mayer is a medical oncologist who specializes in breast cancer. Her research focus is clinical and translational correlative studies in Breast Cancer. She is primarily involved with development of clinical trials addressing novel effective combinations of chemotherapy and biological agents for treatment and prevention, and identification of new markers and predictors of disease.

Her research endeavors have been focused on the role of the following correlated key cell signaling pathways in breast cancer: PI3K/Akt, erbB (EGFR, HER2/neu), and Insulin-like Growth Factor (IGF)-1 pathways. She has been developing hypothesis-driven, translational clinical trials with biologically-based targeted therapeutics that are based on preclinical findings obtained in vitro and/or in vivo in human and murine systems. This will facilitate the process of identifying new molecular targets with prognostic and therapeutic value, and in elucidating mechanisms of therapy resistance for patients with triple-negative, resistant ER-positive and resistant HER2-positive breast cancers.

Clincial Research Description:

My research focus is on new therapeutic strategies focusing on the phosphatidylinositol-3 kinase (PI3K)/Akt and correlated pathways in triple-negative, hormone-refractory and HER2-overexpressing refractory breast cancers, using biologically-based targeted agents. I plan to perform molecular analysis of individual breast cancers in an attempt to determine how the biology of the cancer affects the response to the therapeutic agent. It is also my goal to play a key role in elucidating mechanisms of therapy resistance for patients with triple-negative, resistant ER-positive and resistant HER2-positive breast cancers. Ultimately this will result in better and more rational patient/therapy selection. My role as a clinical investigator are as follows: 1) Develop a Clinical Breast Cancer Research Program with strong links to laboratory efforts throughout the medical center and if necessary, external to the institution. This goal involves collaboration with prestigious investigators within and outside Vanderbilt, and consists of a bidirectional process: observations made in the clinic and correlative studies in tissue samples from clinical trial patients with breast cancer lead basic scientists to investigate new areas of research. Conversely, pre-clinical data focused on relevant signaling pathways in breast cancer are the basis for development and implementation of novel hypothesis-driven clinical trials. 2) Expand preclinical therapeutic testing with tumors freshly obtained from the breast cancer patients in clinical trials. Tissue collection (primary tumor paraffin blocks and/or fresh frozen tissue) in all investigator-initiated breast cancer clinical trials is required for patient enrollment. Thanks to our Multidisciplinary Breast Cancer Clinic, we have been extremely successful in enrolling patients to clinical trials requiring research biopsies. 3) Develop and perform hypothesis-driven, translational clinical trials with biologically-based targeted therapeutics that are based on preclinical findings obtained in vitro and/or in vivo in human and murine systems, to address the most important issues in breast cancer . My research endeavors are focused on the role of the following correlated key cell signaling pathways in breast cancer: PI3K/Akt, erbB (EGFR, HER2/neu), and Insulin-like Growth Factor (IGF)-1 pathways. I have developed targeted-oriented clinical trials addressing the role of these pathways in the development of resistance to antiestrogens and trastuzumab, as well as their role in triple-negative, basal-like tumors. This strategy will provide better understanding of breast cancer biology and of the molecular determinants of clinical efficacy, by optimally characterizing the molecular features of the breast cancer to be treated. This will foster target-assay development in a more limited number of patients. In turn, these results will be instrumental in expediting subsequent development of molecularly targeted agents, providing a platform for prioritization of novel combinations and elucidation of preferential mechanisms of escape from these therapies. Examples of some of my investigator-initiated clinical trials include: VICCBRE0949: A phase I/II study of cisplatin, paclitaxel and RAD001 in patients with metastatic breast cancer VICCBRE0904: A phase II neoadjuvant study of cisplatin, paclitaxel with or without RAD001 in patients with triple-negative locally advanced breast cancer VICCBRE09112: A phase II trial of endocrine therapy in combination with OSI-906 (an IGF-1R inhibitor) and erlotinib (Tarcevaâ„¢, an EGFR inhibitor) in patients with hormone-sensitive metastatic breast cancer VICCBRE0942: A pre-surgical trial of metformin in patients with operable early breast cancer VICCBRE0983: A Prospective Clinical Trial evaluating Potential Biomarkers for Bevacizumab Induced Hypertension

Publications:

Education

  • Doctor of Medicine
    Federal University of Sao Paulo, Sao Paulo, Brazil
    February, 1988 - December, 1993
  • University of Miami School of Medicine, Miami, FL
    Latin American Training Program
    February - June 1994
  • Residency, Internal Medicine
    University of Illinois at Chicago Affiliated Hospitals, Chicago, IL
    July 1994 - June 1997
  • Chief Residency, Internal Medicine
    University of Illinois at Chicago Affiliated Hospitals, Chicago, IL
    July 1997 - June 1998
  • Fellowship, Hematology/OncologyUniversity of Illinois at Chicago Affiliated Hospitals, Chicago, IL
    July 1998 - June 2001
  • Master of Science in Clinical Investigation
    Vanderbilt University School of Medicine, Nashville, TN
    September 2004 - September 2006

You do not have JavaScript enabled. This site works better with JavaScript turned on.